WeVote
Log In

Bill

Bill

SB 796

Compact to Award Prizes for Curing Disease.

2025-2026 Session Introduced by Jim Burgin and 1 co-sponsor

The bill creates a multistate commission to fund and award prizes for curing major diseases, transfer IP to the commission, and fund prizes via public health savings and donations.

Passed 1st Reading
#appropriations;awards #honors&memorials;budgeting;commissions;compacts;dhhs;diseases&healthdisorders;healthservices;interstatecooperation;public;publichealth;research
0
WeVote Research Nonpartisan
Bill Summary · SB 796

Summary of SB 796 (North Carolina, 2025 Session)

Title

Compact to Award Prizes for Curing Diseases

Purpose and Intent

SB 796 would establish North Carolina as part of a multi-state and federal compact designed to fund and administer prizes for curing certain diseases. The bill creates a “Solemn Covenant of States Commission” (the Commission) to oversee prize development, prize funding, and distribution, with the aim of incentivizing research and development toward cures that meet explicit criteria. The mechanism relies on royalty-like funding and public-health savings estimates to finance prize awards.

Key Provisions

Creation and Scope

  • Adds Article 23B to Chapter 90 of the General Statutes, creating a compact among states (and potentially the federal government) to award prizes for cures.
  • Defines key terms, including “Compact,” “Compacting state,” “Non-compacting state,” and “Public health expenses.”

Establishment and Powers of the Commission

  • Once six states enact the compact, the Commission is formed as a corporate entity responsible for liabilities.
  • Each compacting state appoints one representative; qualifications and removal are governed by each state.
  • The Commission has extensive authority, including:
    • Adopting bylaws and rules with binding effect.
    • Receiving and reviewing treatments/therapeutic protocols for cures and awarding prizes meeting defined standards.
    • Controlling the manufacture, distribution, pricing (selling price must cover manufacturing/distribution/governmental costs; non-compacting states may face royalties).
    • Establishing and collecting royalty fees in non-compacting states or foreign countries, capped so total royalties do not exceed estimated five-year public health savings.
    • Managing prize funding through donations, bonds, and loans; maintaining an interest-bearing prize account; and distributing remaining funds as refunds to compacting states.
    • Issuing subpoenas, maintaining offices, borrowing funds, hiring staff, and contracting services.

Prize Rules and Ethics

  • The Commission must define and select at least 10 major diseases for prizes, based on public health impact, survival, and cost considerations.
  • Cure criteria require FDA approval (or legal status enabling manufacture/distribution under the compact), substantial survival benefit, and cure duration under one year.
  • Prize amounts equal the most recent estimated five-year public health savings for the disease across all compacting states, plus donated funds and other factors as determined by the Commission.
  • Upon cure acceptance, the winner must transfer patent and IP rights to the Commission (with limited exceptions if the prize is deemed too low).
  • Public health savings are calculated annually by actuaries; states fund their share of the prize via annual payments tied to actual yearly savings.

Governance and Administrative Details

  • Regular meetings, voting (two-thirds approval required for cure awards), and a structured bylaws framework (including ethics standards, records access, and dispute resolution).
  • A quasi-constitutional framework governs funding, adjustments, and interstate dispute resolution.
  • A management committee (when at least 26 states join) oversees day-to-day operations.
  • Advisory committees may be appointed to monitor operations and advise on major actions.

Financial and Legal Considerations

  • The Commission is tax-exempt and must undergo annual audits.
  • Each compacting state bears its own funding and prize-payment obligations; prizes are not a debt of the state, but of the Commission.
  • Default, withdrawal, expulsion, and dissolution provisions outline consequences, liability for ongoing prize obligations, and steps to terminate the compact.

Affected Entities and Stakeholders

  • Compacting states (including North Carolina if/when it joins) and the Commission.
  • Researchers, developers, and manufacturers seeking prize-winning cures.
  • Patients and public health systems, potentially benefiting from cures and reduced long-term costs.
  • Donors and funders contributing to prize pools.

Timeline and Funding

  • The compact becomes effective after enactment by at least two compacting states, with the Commission established after six states join.
  • North Carolina would appropriate $100,000 in nonrecurring funds for 2026-2027 to cover implementation costs, contingent on the compact becoming effective by June 30, 2027.
  • The act’s effective dates: Section 2 (appropriation) becomes July 1, 2026; the rest becomes effective only after the compact is enacted by at least two states.

Overall Impact

If enacted and the compact becomes effective, NC would participate in a federally/internationally coordinated prize system intended to accelerate cures for major diseases through a funded, rules-based framework that blends public health savings with private and charitable support. The approach centralizes prize design, IP transfer to the Commission, and intergovernmental governance, while imposing funding and compliance requirements on member states.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.